The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Argos Therapeutics; AVEO; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Novartis; Pfizer; Prometheus; Schering-Plough; Wyeth
Research Funding - Acceleron Pharma (Inst); Argos Therapeutics; Argos Therapeutics (Inst); AstraZeneca (Inst); AVEO; AVEO (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Celgene; Celgene (Inst); EntreMed; Exelixis; Genentech; GlaxoSmithKline; immatics; Lilly; MedImmune; Millennium (Inst); Novartis; Pfizer; Prometheus; Roche Pharma AG; Schering-Plough; Synta; Threshold Pharmaceuticals; TRACON Pharma (Inst); Wyeth
 
Consulting or Advisory Role - Algeta ASA; Astellas Pharma; AVEO; Bayer; Medivation; Novartis; Sanofi
Research Funding - GlaxoSmithKline
Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC).
 
Elizabeth R. Plimack
Consulting or Advisory Role - Astellas Pharma; Dendreon; Genentech; GlaxoSmithKline; Merck; Novartis
Research Funding - Acceleron Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending (Inst)
 
Hans J. Hammers
Honoraria - Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb
 
Brian I. Rini
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Immatics (Inst); Millennium (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer
 
David F. McDermott
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Roche; Merck; Pfizer
Research Funding - Prometheus
 
Bruce Redman
No Relationships to Disclose
 
Timothy Kuzel
Honoraria - Amgen; Argos Therapeutics; Astellas Pharma; Bayer/Onyx; Bionomics; Celgene; Eisai; Genentech/Roche; Janssen
Speakers' Bureau - Astellas Pharma; Bayer; Celgene; Genentech/Roche; Janssen Oncology
Research Funding - Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); CureTech (Inst); Eisai (Inst); Genentech/Roche (Inst); MedImmune (Inst); Merck/Schering Plough (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Argos Therapeutics; Astellas Pharma; Bayer/Onyx; Celgene; elorac; Genentech; Janssen Oncology
 
Michael Roger Harrison
Honoraria - Novartis; Prometheus
Consulting or Advisory Role - AVEO; Bayer; Exelixis; Novartis
Research Funding - Argos Therapeutics; Bristol-Myers Squibb; Dendreon; Exelixis; Janssen; Pfizer
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Research Funding - Astellas Pharma; Exelixis; Novartis
 
Harry A. Drabkin
No Relationships to Disclose
 
Saby George
No Relationships to Disclose
 
Theodore F. Logan
No Relationships to Disclose
 
Kim Allyson Margolin
Consulting or Advisory Role - Nektar; NeoStem; Oncosec; Prothena
 
Li-an Xu
Employment - Bristol-Myers Squibb
 
Ian Waxman
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Robert Motzer
Consulting or Advisory Role - Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline